drugset / Trial / NCT04480710
A Study of CRV431 Dosed Once Daily in NASH Induced F2 and F3 Subjects
RandomizedParallel-groupSingle-blindTreatment
Summary
This is a randomized, single-blind, placebo-controlled, once daily (QD) dose study of CRV431 in presumed NASH F2/F3 subjects.
Timeline
- Start
- 2020-06-23
- Primary completion
- 2021-06-29
- Completion
- 2021-10-30
Outcome
Met primary endpoint
release “All primary endpoints of the AMBITION NASH trial (safety, tolerability and pharmacokinetics) were met.” hepionpharma.com ↗
release “Study met safety, tolerability, and pharmacokinetics primary endpoints” hepionpharma.com ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | rencofilstat | Small molecule | 75 mg | — |
| Subject | rencofilstat | Small molecule | 225 mg | — |